Background Psoriasis is a chronic inflammatory skin disease, which requires long‐term, safe
and effective treatment. Apremilast, a small‐molecule PDE 4 inhibitor, has been introduced …

Background Little has been published on the real‐world effectiveness and safety of
apremilast in psoriasis. Objectives To evaluate the effectiveness, safety and drug survival of …

Background Apremilast, an oral phosphodiesterase‐4 inhibitor, has demonstrated efficacy in
patients with moderate to severe psoriasis. Objective To evaluate long‐term efficacy and …

Background Apremilast is a novel oral phosphodiesterase‐4 inhibitor approved for psoriasis
treatment. Randomized trials have documented its efficacy and safety, but data on real …

Background Apremilast, an oral, small‐molecule phosphodiesterase 4 inhibitor, has
demonstrated efficacy in patients with moderate‐to‐severe psoriasis. Objective Evaluate …

Introduction Psoriasis is a systemic inflammatory disease characterised by pruritic skin
lesions that impair quality of life (QOL). Long-Term Documentation of the Utilization of …

Background APPRECIATE is a multinational, observational, retrospective, cross‐sectional
study in patients treated for psoriasis with apremilast, an oral phosphodiesterase 4 inhibitor …

BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite
broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated …

Abstract Introduction/Background Manifestations of psoriasis in special areas are difficult to
treat and are associated with a high disease burden and significant quality of life (QoL) …

INTRODUCTION: Many options are available for patients with moderate to severe plaque
psoriasis. Patients with moderate disease, however, are often undertreated and do not …